Marimed (MRMD) Net Income towards Common Stockholders (2011 - 2026)

Marimed (MRMD) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$3.8 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 31.25% year-over-year to -$3.8 million in Q1 2026; TTM through Mar 2026 was -$12.6 million, a 22.92% increase from a year earlier, with the FY2025 full-year figure at -$14.5 million, down 16.3% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$3.8 million, up from -$4.6 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for MRMD reached as high as $4.7 million in Q4 2022 and fell as low as -$10.1 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$1.9 million across 5 years, with a median of -$1.3 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders soared 174.13% in 2022 and slumped 324.07% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $4.7 million in 2022, then plunged by 313.5% to -$10.1 million in 2023, then gained by 18.49% to -$8.3 million in 2024, then soared by 43.84% to -$4.6 million in 2025, then increased by 18.83% to -$3.8 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$3.8 million in Q1 2026, -$4.6 million in Q4 2025, and -$2.9 million in Q3 2025.